Related Experiment Videos
Pretreatment with sufentanil reduces myoclonus after etomidate
L Hueter1, K Schwarzkopf, M Simon
1Klinik fuer Anesthesiologie und Intensivtherapie, Friedrich-Schiller-Universitaet Jena, Germany. lars.hueter@med.uni-jena.de
Acta Anaesthesiologica Scandinavica
|April 16, 2003
Summary
Pretreating with sufentanil effectively prevents etomidate-induced myoclonus, a common anesthesia side effect. This study found no myoclonic movements in patients receiving sufentanil before etomidate induction.
Area of Science:
- Anesthesiology
- Pharmacology
Background:
- Myoclonic movements frequently occur during general anesthesia induction with etomidate.
- Investigating interventions to mitigate etomidate-induced myoclonus is crucial for patient safety.
Purpose of the Study:
- To evaluate the efficacy of sufentanil pretreatment in reducing etomidate-induced myoclonus.
- To assess the safety profile of sufentanil when used prior to etomidate administration.
Main Methods:
- A double-blind, randomized study involving 40 female patients (ASA I-III).
- Patients received either sufentanil (0.3 µg/kg) or placebo 150 seconds before etomidate (0.3 mg/kg) induction.
- Myoclonic movements, dizziness, respiratory rate, blood pressure, and heart rate were monitored.
Main Results:
- No patients (0%) in the sufentanil group exhibited myoclonic movements post-etomidate.
- 16 patients (80%) in the placebo group experienced etomidate-induced myoclonus (P<0.01).
- No instances of apnea were observed in the sufentanil group before anesthetic induction.
Conclusions:
- Sufentanil at 0.3 µg/kg is a safe and effective prophylactic agent against etomidate-induced myoclonus.
- Pretreatment with sufentanil significantly reduces the incidence of myoclonic movements without adverse effects.